相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala et al.
CLINICAL CANCER RESEARCH (2014)
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
Jonathan L. Curry et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2014)
Resistance to RAF Inhibitors Revisited
Edward Hartsough et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-Expressing Melanoma
Edward J. Hartsough et al.
MOLECULAR CANCER RESEARCH (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Hubing Shi et al.
CANCER DISCOVERY (2014)
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Rizwan Haq et al.
CANCER CELL (2013)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
BRAF in Melanoma: Current Strategies and Future Directions
April K. S. Salama et al.
CLINICAL CANCER RESEARCH (2013)
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan et al.
CLINICAL CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Taru Muranen et al.
CANCER CELL (2012)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
K. J. Basile et al.
ONCOGENE (2012)
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Anindita Chakrabarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
Yongping Shao et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Kristy J. Wilson et al.
PHARMACOLOGY & THERAPEUTICS (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
D. M. Owens et al.
ONCOGENE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Energy metabolism in tumor cells
Rafael Moreno-Sanchez et al.
FEBS JOURNAL (2007)
The significance of mitochondrial toxicity testing in drug development
James A. Dykens et al.
DRUG DISCOVERY TODAY (2007)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Coordinating ERK/MAPK signalling through scaffolds and inhibitors
W Kolch
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Modulation of signalling by sprouty: A developing story
HJ Kim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
